API | arformoterol

arformoterol (brovana) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem repoDB

Active Ingredient History

NOW

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD). ^Wikipedia

Chemistry

SMILES: COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1
InChIKey: BPZSYCZIITTYBL-YJYMSZOUSA-N
Mol. Mass: 344.41
ALogP: 2.22 Partition coefficient
ChEMBL Molecules:

arformoterol

arformoterol tartrate

More Chemistry

Pharmacology

Mechanism of Action:
- Beta-2 adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Topical
Pro Drug: No

Drug Pricing (per unit)

United States

$4.5025 - $18.0329

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (22)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (3)

Asthma (approved 2001)

Emphysema

Pulmonary Disease, Chronic Obstructive

Experimental Indications - Clinical Trial Phases 1-4 (8)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 4)

Asthma, Exercise-Induced (Phase 3)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Coronavirus Infections (Phase 2)

Emphysema ()

Pulmonary Disease, Chronic Obstructive ()

Overview

Highest Phase: Phase 4
# of Trials: 21
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue